WSJ What’s News: Who Is Winning the Obesity-Drug Arms Race?

Date: November 4, 2025
Host: David Wehner
Guest: Peter Loftus (WSJ Pharma Reporter)

Episode Overview

This episode dives into the evolving landscape of the pharmaceutical industry, spotlighting the transformative impact of GLP-1 weight loss drugs like Mounjaro and Zepbound. As Eli Lilly surges ahead with record-breaking earnings, competitors scramble to respond—most notably, Novo Nordisk and Pfizer are engaged in a dramatic acquisition fight. The discussion extends to how traditional pharmaceutical giants are coping with looming patent expirations, and what the latest moves in drug pricing and tariffs under President Trump mean for the industry’s future.

Key Discussion Points & Insights

1. Eli Lilly’s Dominance in Weight Loss Drugs

• Unprecedented Sales Growth:
  • Eli Lilly's GLP-1 drugs, especially Mounjaro and Zepbound, are driving explosive growth.
  • Peter Loftus [01:46]: “When you have a couple of drugs that are in demand because they're so effective for weight loss and diabetes…you can basically print money."
• Resolving Supply Issues: Supply constraints have been mitigated, further fueling growth.
• Global Reach Beyond the U.S.:
  • International rollout is robust, with growing demand from patients paying out-of-pocket.
  • Peter Loftus [02:32]: “Much of the demand...is from people who are willing to pay out of pocket for it in these other countries. If that keeps up, the market's just going to get bigger and bigger.”
• Sustainability Questions:
  • Concerns arise about how long this boom can last as broader access could introduce pricing pressure.
  • Peter Loftus [02:48]: "As these drugs roll out to more and more people, there's going to be more and more pricing pressure that moderates the overall sales growth.”

2. Rivalry & M&A Drama: Novo Nordisk vs. Pfizer

• Takeover Battle:
  • Novo Nordisk has made an aggressive, unexpected bid to acquire Matsera from Pfizer.
  • David Wehner [02:55]: “Just as Eli Lilly was reporting earnings, Novo Nordisk was coming in with an out-of-nowhere aggressive bid…”
• Pfizer’s Response:
  • Legal action underway by Pfizer to enforce its original merger terms with Matsera.
  • Peter Loftus [03:10]: “They’ve already filed a couple legal moves...turned into this juicy or contentious takeover battle…”
• National Sentiment in Pharma M&A:
  • Pfizer publicly flags Novo’s bid as a foreign (non-American) threat.
  • CEO Albert Bourla’s relationship with the White House and prior drug-pricing deal becomes part of the narrative.

3. Drug Pricing and Tariff Negotiations with the Administration

• Recent Deals and Limited Scope:
  • September’s Pfizer–White House agreement offered relief, with concessions mainly affecting Medicaid rather than the broader market.
  • Peter Loftus [03:51]: “It’s limited to reduced prices in Medicaid, where most companies already sell at a discount...less of an impact than it might seem.”
• Tariff Protections:
  • Companies hope for protection from new tariffs by making limited pricing concessions.
• Market Reactions:
  • Stock prices have risen as details signal limited overall revenue impact for pharma.

4. Patent Expirations – The ‘Patent Cliff’ Challenge

• Major Drugs Facing Expiry:
  • Blockbusters such as Merck’s Keytruda and AbbVie’s Humira are losing or have lost patent exclusivity, jeopardizing future revenue.
• Coping Strategies:
  • Acquisitions: Pharma giants are purchasing other companies or new drugs to offset anticipated losses.
  • In-House R&D: Development of new drugs targeting similar conditions, e.g., AbbVie betting on Skyrizi as Humira’s replacement.
  • Cost-Cutting: Companies like Bristol Myers and Merck are reducing expenses to buffer against revenue decline.
  • Peter Loftus [05:56]: “Acquisitions are a big way they're doing it...Introducing new drugs that treat some of the similar conditions to the older ones that lost patent protection...Some companies have cut costs to get ready for this patent cliff...”

5. Looking Forward – Industry Uncertainty and Resilience

• Unsolved Questions:
  • Whether the GLP-1-driven revenue surge will be sustained or diminished by price pressures and competitive dynamics.
• Winners to Watch:
  • All eyes on how Eli Lilly, Novo Nordisk, Pfizer, and legacy giants like Merck and AbbVie navigate the complex mix of new drug development, pricing politics, and global expansion.

Notable Quotes & Memorable Moments

• Peter Loftus on Lily’s Market Power [01:46]:

  “When you have a couple of drugs that are in demand because they’re so effective for weight loss and diabetes, and when you resolve some supply issues, as Eli Lilly has done, that you can basically print money.”

• On Out-of-Pocket Growth Abroad [02:32]:

  “Much of the demand for it is from people who are willing to pay out of pocket for it in these other countries. If that keeps up, the market’s just going to get bigger and bigger.”

• On Market Realities of Price Concessions [03:51]:

  “The impact is more limited in scope than it might seem…through this direct purchase model, including Trump rx, investors and analysts see that as having less of an impact than it might seem.”

• On Threats and Change [05:56]:

  “Acquisitions are a big way they’re doing it...Some companies have cut costs to get ready for this patent cliff like Bristol Myers and Merck. And so there’s a variety of ways that they’re all trying to weather this patent cliff.”

Timestamps for Key Segments

• 00:33 – Earnings season opening: Eli Lilly sets the pace
• 01:46 – Eli Lilly’s explosive sales & global GLP-1 growth
• 02:55 – Novo Nordisk’s surprise bid, Pfizer’s legal response
• 03:51 – Drug pricing negotiations, tariffs, and market implications
• 05:29 – Patent cliffs: how pharma giants strategize for post-exclusivity
• 07:01 – Wrap-up and reflections

Tone and Language

The episode maintains the WSJ’s clear, analytical, and slightly urgent tone, reflecting the high stakes and rapid developments in the pharmaceutical industry. Comments are factual but often laced with a sense of drama, especially regarding high-profile corporate maneuvering and the “arms race” for market-defining drugs.

A must-listen episode for investors, industry watchers, and anyone interested in how a few revolutionary drugs can reshape a sector—and the battles raging to control the profits and risks that come with them.